Does Rallies show Form 4 insider transactions for RARE?

Yes. Rallies tracks RARE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RARE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RARE. It does not provide personalized investment advice.

RARE (Ultragenyx Pharmaceutical Inc.) Stock Analysis - Insider Trades

Ultragenyx Pharmaceutical Inc. (RARE) is a publicly traded Healthcare sector company. As of May 21, 2026, RARE trades at $24.00 with a market cap of $2.38B and a P/E ratio of -3.82. RARE moved +4.14% today. Year to date, RARE is +1.13%; over the trailing twelve months it is -37.43%. Its 52-week range spans $18.29 to $58.00. Analyst consensus is strong buy with an average price target of $48.86. Rallies surfaces RARE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RARE stock inside the company?

Recent RARE insider activity includes SULIMAN SHEHNAAZ sold 5.74K, Crombez Eric sold 344, Horn Howard sold 4.68K, Horn Howard sold 4.68K, and Parschauer Karah Herdman sold 3.51K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RARE Key Metrics

Key financial metrics for RARE
Metric	Value
Price	$24.00
Market Cap	$2.38B
P/E Ratio	-3.82
EPS	$-6.10
Dividend Yield	0.00%
52-Week High	$58.00
52-Week Low	$18.29
Volume	1
Avg Volume	0
Revenue (TTM)	$669.71M
Net Income	$-608.92M
Gross Margin	0.00%

Recent RARE Insider Trades

SULIMAN SHEHNAAZ sold 5.74K (~$144.19K) on May 18, 2026.
Crombez Eric sold 344 (~$8.59K) on May 5, 2026.
Horn Howard sold 4.68K (~$116.61K) on May 1, 2026.
Horn Howard sold 4.68K (~$98.20K) on Apr 1, 2026.
Parschauer Karah Herdman sold 3.51K (~$79.53K) on Mar 10, 2026.

Latest RARE News

Ultragenyx Q1 Loss Widens as Crysvita Sales Falter, Evkeeza and Dojolvi Rise — May 6, 2026
Ultragenyx Secures FDA Acceptance for UX111 BLA With Sept. 19, 2026 PDUFA Date — Apr 2, 2026
Ultragenyx Buy Rating Reiterated while DTX301 Trial Reduces Ammonia, Stock Falls 3.46% — Mar 12, 2026
Ultragenyx’s DTX301 Achieves 18% Ammonia Reduction and 27% Scavenger Med Cut at Week 36 — Mar 12, 2026
FDA Accepts DTX401 Gene Therapy BLA for GSDIa with August PDUFA Date — Feb 23, 2026

RARE Analyst Consensus

15 analysts cover RARE: 0 strong buy, 13 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $48.86.

Common questions about RARE

Who is trading RARE stock inside the company?: Recent RARE insider activity includes SULIMAN SHEHNAAZ sold 5.74K, Crombez Eric sold 344, Horn Howard sold 4.68K, Horn Howard sold 4.68K, and Parschauer Karah Herdman sold 3.51K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RARE?: Yes. Rallies tracks RARE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RARE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RARE. It does not provide personalized investment advice.